取卵同期行卵巢子宫内膜异位囊肿硬化治疗的前瞻性可行性队列研究
结果显示囊肿体积显著缩小,疼痛与生活质量改善,卵巢储备标志物保持稳定,出现1例Clavien-Dindo III级并发症(感染需手术干预)。
要点
- 取卵同期乙醇硬化治疗子宫内膜异位囊肿可行,囊肿体积显著缩小。
- VAS疼痛评分与EHP-30总分显著改善,AMH保持稳定。
- 出现1例Clavien-Dindo III级感染并发症,需手术干预。
核心结论
- 该试点研究提示,取卵同期行乙醇硬化治疗子宫内膜异位囊肿是可行的微创方法,与囊肿体积大幅缩小及疼痛、生活质量改善相关。
主要发现
- 囊肿体积从干预前均值(SD)53.04(39.34)cm3降至3个月时8.32(9.20)cm3(p = .002)。
- VAS评分从7.24(1.82)降至5.53(2.63)(p = .037),EHP-30总分从78.35(17.92)改善至48.53(18.95)(p < .001)。
- AMH从2.50(2.03)ng/mL变为2.37(1.94)ng/mL(p = .82),AFC从9.50(6.16)个增至14.10(8.33)个(p = .03)。
- 发生1例Clavien-Dindo III级并发症(感染需手术干预)。
关键数值与推荐
- 纳入标准为单侧子宫内膜异位囊肿≥3 cm或双侧囊肿且至少1个>3 cm。
- 干预为经阴道取卵后行超声引导乙醇硬化治疗。
- 主要评估囊肿体积缩小及VAS、EHP-30症状改善。
- 次要结局为术前与3个月随访时AFC和AMH变化。
临床怎么用
- 对寻求生育力保存的子宫内膜异位囊肿患者,可考虑取卵同期行乙醇硬化治疗以减少囊肿体积并改善症状。
- 需告知患者存在感染等需手术干预的并发症风险。
- 结果仅为初步假设生成,需对照比较研究验证。
局限性
- 随访仅至3个月,长期疗效与安全性未知。
- 结果为初步假设生成性,需控制性比较研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the feasibility, safety, and preliminary efficacy of concurrent transvaginal ovarian puncture for oocyte retrieval and ethanol sclerotherapy of ovarian endometriomas (eSCLT) during controlled ovarian stimulation. DESIGN: Prospective single-center pilot cohort study with a before-after design and no randomization. SETTING: Assisted Reproductive Technology Unit of a public tertiary hospital in Spain. PATIENTS: Twenty-three women aged 18 to 40 years seeking fertility preservation, presenting with unilateral endometrioma ≥3 cm or bilateral endometrioma with at least 1 cyst >3 cm. INTERVENTIONS: Combined transvaginal oocyte pick-up followed by ultrasound-guided eSCLT. MEASUREMENTS AND MAIN RESULTS: Endometrioma volume reduction and symptomatic improvement assessed by Visual Analog Scale (VAS) pain scores and Endometriosis Health Profile-30 (EHP-30). Secondary outcomes included variations in ovarian reserve parameters (antral follicle count [AFC] and anti-Müllerian hormone [AMH] assessed before the procedure and at 3-month follow-up). Endometrioma volume showed a statistically significant reduction from a mean (SD) of 53.04 (39.34) cm3 pre-intervention to 8.32 (9.20) cm3 at 3 months (p = .002). VAS scores decreased from 7.24 (1.82) to 5.53 (2.63) (p = .037), and EHP-30 total scores improved from 78.35 (17.92) to 48.53 (18.95) (p < .001). Ovarian reserve markers remained stable (AMH: 2.50 [2.03] vs 2.37 [1.94] ng/mL, p = .82; AFC increased from 9.50 [6.16] to 14.10 [8.33] follicles, p = .03). One Clavien-Dindo Grade III complication (infection requiring surgical intervention) occurred. CONCLUSION: This pilot study suggests that combined oocyte vitrification and eSCLT is a feasible minimally invasive approach associated with substantial cyst volume reduction and improvements in pain and quality of life. These findings should be interpreted as preliminary and hypothesis-generating, warranting validation in controlled comparative studies.
引用
- Tudela CL, Navarro LG, García AV, et al. Sclerotherapy of Ovarian Endometriomas During Oocyte Preservation: A Prospective Feasibility Cohort Study. J Minim Invasive Gynecol. 2026. PMID: 42476497. doi:10.1016/j.jmig.2026.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。